AnalystBro Research

Research

Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.

2 articles.

Company · DSE:JMISMDL · Pharmaceuticals & healthcare (medical devices) · Analysis · 31 Oct 2026

JMI Syringes: gross margin fell to 8.7% in 9M FY2026 and a flood write-off took FY2026 to a BDT 2.00 loss per share; the 10% cash dividend was kept

Revenue fell 14.7% in the nine months to March 2026, gross margin dropped from 15.0% to 8.7%, and BDT 75.4m of flood-damaged inventory not covered by insurance was written off. Nipro Corporation of Japan owns 50.23%; the balance sheet carries almost no debt.

Company · DSE:JHRML · Pharmaceuticals & healthcare (medical devices) · Analysis · 31 Oct 2026

JMI Hospital Requisite: device sales fell 10.7% in FY2025 and a new hospital cut FY2026 EPS to BDT 0.71; BDT 745m is lent to sister companies

Revenue fell from BDT 1,870m to 1,671m in FY2025 and 9M FY2026 sales were 6.1% lower again; the Apollo-licensed hospital opened in August 2025 and lost about BDT 81m in nine months. Interest charged to group companies was 30% of FY2025 pre-tax profit.